Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, announced today the expansion of the Global Diagnostics Network (GDN), a strategic working group of major diagnostic laboratories collaborating to generate enhanced diagnostics insights to improve the delivery of global healthcare. Regional companies LSI Medience, and Strand Life Sciences join Quest and the charter members — Al Borg Medical Laboratories, Dasa, GC Labs, Healius, KingMed Diagnostics, SYNLAB – as GDN members.
“We welcome these two new GDN members and are eager to continue acceleration of the network’s programs that will reach patients in every part of the world,” said Mark Machulcz, General Manager of Global Markets at Quest Diagnostics. “Since launching in October 2018, the GDN has made great strides in increasing access to diagnostic technology innovation, and in building the largest global launch platform for rapid deployment of companion diagnostics.”
Collectively, this worldwide community of nine leading healthcare companies has a presence in countries with two-thirds of the world’s population, and over 90% of the global pharmaceutical market.
“Global access to companion diagnostics through the GDN will enable faster, higher quality, and consistent delivery of precision medicine to healthcare systems and patients around the world,” commented Dr. Jay Wohlgemuth, Chief Medical Officer at Quest Diagnostics. “The GDN also provides us with the ability to develop rapid and proactive responses to potentially pandemic emerging pathogens and to better understand how to interpret genetic and other lab testing results based on geography and ethnicity – a significant unmet need in our industry. We are excited that the GDN is expanding and eager to recognize its potential.” – PR Newswire